Imipenem/Cilastatin Steriscience

Imipenem and Cilastatin, the active ingredient in Imipenem/Cilastatin Steriscience, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, skin and soft tissue infections, lower respiratory tract infections and sepsis in hospitalized adults.

GNH USA supplies Imipenem/Cilastatin Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems. - Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: achieves bacterial eradication in resistant Gram‑negative and Gram‑positive organisms. - Skin and soft tissue infections: delivers rapid bactericidal activity against common skin pathogens. - Hospital‑acquired pneumonia (including ventilator‑associated): ensures effective treatment of multidrug‑resistant respiratory pathogens. - Severe sepsis and septic shock: contributes to rapid bacterial clearance in critically ill patients.

Adverse reactions to Imipenem/Cilastatin may vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: mild skin erythema or pruritus. - Injection site pain: discomfort at the infusion site.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: potentially life‑threatening intestinal infection.

When prescribing Imipenem/Cilastatin, clinicians should consider several precautionary measures to minimise risk. - Renal function assessment: adjust dose in patients with impaired kidney function. - History of seizures: avoid or monitor closely in individuals with prior seizure disorders. - Allergy evaluation: confirm no known hypersensitivity to β‑lactam antibiotics. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Use in pregnancy: weigh potential benefits against unknown fetal risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may decrease valproate concentrations, risking seizure breakthrough. - Carbapenem antibiotics with probenecid: can increase nephrotoxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate electrolyte disturbances. - Anticoagulants (warfarin): monitor INR for possible changes. - CNS depressants: observe for enhanced central nervous system effects.